V F Antoniv, K V Efimochkina, T V Antoniv, V I Popadiuk, A U Kakupshev
Index: Vestn. Otorinolaringol. (2) , 57-60, (2012)
Full Text: HTML
The objective of the present comparative study was to estimate the efficacy of the treatment of neurosensorial hearing loss (NSHL) with the use of milgamma, milgamma compositum, and vitamins B1 and B2 monotherapy. The best results were obtained after the treatment with milgamma and milgamma compositum. It is concluded that the use of these preparations for the combined treatment of neurosensorial hearing loss is pathogenetically justified since it permits to achieve the improvement of the functional state of the cochleovestibular nerve and the enhancement of patient compliance; moreover, it reduces the work load on the medical personnel.
| Structure | Name/CAS No. | Molecular Formula | Articles |
|---|---|---|---|
![]() |
Benfotiamine
CAS:22457-89-2 |
C19H23N4O6PS |
|
Benfotiamine, a synthetic S-acyl thiamine derivative, has di...
2008-01-01 [BMC Pharmacol. 8 , 10, (2008)] |
|
The detrimental effects of acute hyperglycemia on myocardial...
2014-06-06 [Life Sci. 105(1-2) , 31-42, (2014)] |
|
The effect of benfotiamine on mu-opioid receptor mediated an...
2014-03-01 [Exp. Clin. Endocrinol. Diabetes 122(3) , 173-8, (2014)] |
|
Boosting the pentose phosphate pathway restores cardiac prog...
2013-01-01 [Cardiovasc. Res. 97(1) , 55-65, (2013)] |
|
Advanced glycation end-products inhibition improves endothel...
2012-02-01 [Int. J. Rheum. Dis. 15(1) , 45-55, (2012)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved
